Business · 24/09/2012
FDA Requests Patient Stakeholder Notification for Patient-Focused Drug Development Meetings
The FDA is seeking patient stakeholders to notify their intention to participate in periodic meetings to discuss the development of patient-focused drugs, as part of the Prescription Drug User Fee Act V, to ensure consistent representation and progress in these discussions.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →